Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer

21Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Cancer is the second leading cause of death and there is an urgent need to improve cancer management. We have developed an innovative cancer therapy named Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) by combining gold nanostars (GNS)-mediated photothermal ablation with checkpoint inhibitor immunotherapy. Our previous studies have demonstrated that SYMPHONY photoimmunotherapy not only treats the primary tumor but also dramatically amplifies anticancer immune responses in synergy with checkpoint blockade immunotherapy to treat remote and unresectable cancer metastasis. The SYMPHONY treatment also induces a 'cancer vaccine' effect leading to immunologic memory and prevents cancer recurrence in murine animal models. This manuscript provides an overview of our research activities on the SYMPHONY therapy with plasmonic GNS for cancer treatment.

Cite

CITATION STYLE

APA

Liu, Y., Chorniak, E., Odion, R., Etienne, W., Nair, S. K., Maccarini, P., … Vo-Dinh, T. (2021, September 2). Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer. Nanophotonics. De Gruyter Open Ltd. https://doi.org/10.1515/nanoph-2021-0237

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free